Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen

Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

A number of other brokerages have also recently weighed in on ACRV. HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of Acrivon Therapeutics in a report on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Finally, Piper Sandler lifted their price objective on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Acrivon Therapeutics Price Performance

ACRV stock opened at $1.51 on Friday. Acrivon Therapeutics has a 1 year low of $1.05 and a 1 year high of $5.75. The company has a 50 day simple moving average of $1.94 and a 200 day simple moving average of $1.91. The stock has a market cap of $47.66 million, a price-to-earnings ratio of -0.71 and a beta of 1.74.

Insider Transactions at Acrivon Therapeutics

In other Acrivon Therapeutics news, CEO Peter Blume-Jensen acquired 49,000 shares of the company’s stock in a transaction on Wednesday, January 14th. The stock was acquired at an average cost of $1.68 per share, with a total value of $82,320.00. Following the purchase, the chief executive officer directly owned 2,095,771 shares of the company’s stock, valued at approximately $3,520,895.28. This represents a 2.39% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have purchased 67,832 shares of company stock worth $114,534. Company insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

Several institutional investors have recently made changes to their positions in the company. UBS Group AG lifted its stake in shares of Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after purchasing an additional 682,763 shares during the period. Marshall Wace LLP raised its position in shares of Acrivon Therapeutics by 231.4% in the fourth quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock worth $1,196,000 after acquiring an additional 346,366 shares during the period. Jane Street Group LLC purchased a new stake in shares of Acrivon Therapeutics during the 2nd quarter worth about $371,000. Two Sigma Investments LP grew its position in shares of Acrivon Therapeutics by 76.2% during the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock valued at $578,000 after acquiring an additional 138,033 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Acrivon Therapeutics in the 2nd quarter valued at about $126,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.